PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer-Reference-Cited by-同舟云学术

PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer

Published:2019-02-11 Issue:3 Volume:129 Page:1211-1228
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Chabanon Roman M.,Muirhead Gareth,Krastev Dragomir B.^ORCID,Adam Julien,Morel Daphné^ORCID,Garrido Marlène^ORCID,Lamb Andrew,Hénon Clémence,Dorvault Nicolas,Rouanne Mathieu^ORCID,Marlow Rebecca^ORCID,Bajrami Ilirjana,Cardeñosa Marta Llorca,Konde Asha,Besse Benjamin,Ashworth Alan,Pettitt Stephen J.^ORCID,Haider Syed,Marabelle Aurélien^ORCID,Tutt Andrew N.J.^ORCID,Soria Jean-Charles,Lord Christopher J.^ORCID,Postel-Vinay Sophie

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://www.jci.org/articles/view/123319/files/pdf

Reference56 articles.

1. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

2. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

3. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study

4. Genomic Features of Response to Combination Immunotherapy in Lung Cancer

5. Mutational Landscape and Sensitivity to Immune Checkpoint Blockers

Cited by 240 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanism of immune activation mediated by genomic instability and its implication in radiotherapy combined with immune checkpoint inhibitors;Radiotherapy and Oncology;2024-10

2. METTL3 inhibition-activated cGAS/STING axis enhances immunotherapy and PARP inhibitor sensitivity of lung carcinoma;2024-09-06

3. Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma;npj Precision Oncology;2024-09-05

4. Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer;Journal of Translational Medicine;2024-08-21

5. Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer;Frontiers in Oncology;2024-08-02